CID-103 vs Lumrotatug

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: CD38 · full Multiple Myeloma pipeline

CID-103

Developed by CASI Pharmaceuticals, Inc.

Phase 1 in Multiple Myelomamonoclonal antibody (fully human IgG1, anti-CD38)
Weak signal

NCT04758767 · Phase 1 · completed

All participants received CID-103 with no placebo or comparator arm and no blinding, so the design cannot show whether the antibody works better than another option. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Adverse events (approximately 18 months after study start): In 10 patients with previously treated relapsed and/or refractory multiple myeloma, CID-103 given as 30 mg/150 mg, 150 mg/300 mg, 150 mg/600 mg and 150 mg/900 mg doses was generally safe and well tolerated overall, but there was no beneficial impact on any patient's multiple myeloma. Nine of the 10 patients discontinued study drug due to progressive disease or lack of clinical benefit, and no further clinical trials with CID-103 are planned. (not_applicable)

Result source: NCT04758767

Lumrotatug

Developed by Timberlyne Therapeutics and partners

Phase 3 in Multiple Myelomamonoclonal antibody (humanized, anti-CD38)
Weak signal

NCT04818372 · Phase 1 · status unknown

This is an early, single-arm, open-label safety and dose-finding study with no randomization or comparator group, so it cannot show whether CM313 works better than another treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: May 2030 · NCT07910903 (registry estimate)

Reported efficacy

Dose escalation: Number of Participants with a Dose-Limiting Toxicity (DLT) (Up to 21 days after the first dose); Dose escalation and Dose expansion: Incidence, severity, and outcome of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 (Up to 30 days after the last dose of CM313 or until the start of subsequent anticancer therapy, if earlier); Dose expansion: To evaluate the activity of CM313 in combination with Rd/Dexamethasone as assessed by overall response rate (ORR) in RRMM patients (Up to 24 months): CM313 phase 1 dose-escalation/expansion (NCT04818372, anti-CD38 mAb, R/R multiple myeloma + marginal zone lymphoma): grade>=3 TEAEs 15/34 (44.1%), no DLTs; ORR 34.5% among 29 evaluable RRMM patients; median PFS 132 days.

Result source: NCT04818372

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCID-103Lumrotatug
PFS, median—Not reported—Trial running · NCT07910903
OS, median—Not reported—Trial running · NCT07910903
ORR—Not reported—Trial running · NCT07910903
VGPR or better—Not reported—Trial running · NCT07910903
MRD negativity—Not reported—Trial running · NCT07910903

PFS, median

CID-103
—Not reported
Lumrotatug
—Trial running · NCT07910903

OS, median

CID-103
—Not reported
Lumrotatug
—Trial running · NCT07910903

ORR

CID-103
—Not reported
Lumrotatug
—Trial running · NCT07910903

VGPR or better

CID-103
—Not reported
Lumrotatug
—Trial running · NCT07910903

MRD negativity

CID-103
—Not reported
Lumrotatug
—Trial running · NCT07910903
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

CID-103: no structured comparison results are available for Multiple Myeloma.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Lumrotatug
CM313 phase 1 dose-escalation/expansion (NCT04818372, anti-CD38 mAb, R/R multiple myeloma + marginal zone lymphoma): grade>=3 TEAEs 15/34 (44.1%), no DLTs; ORR 34.5% among 29 evaluable RRMM patients; median PFS 132 days. NCT04818372 · Phase 1 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CID-103's landscape · Lumrotatug's landscape